We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
National spending on prescription drugs ballooned five-fold in 2014, with much of it going toward specialty drugs, according to a new report from the Centers for Medicare & Medicaid Services. Read More
The UK’s pricing watchdog said it does not recommend reimbursement for Alexion’s Strensiq because it does not provide enough value for its high price. Read More
Drugmarkers are reporting a 20 percent improvement in securing their supply chains compared with a year ago, according to findings from a new report. Read More
The European Medicines Agency is moving to reject substitute proof-of-concept trials in place of GCP noncompliant studies during marketing application reviews. Read More
A recent report suggests the advisory committees that the FDA relies upon to ensure medical products are safe and effective can be wildly inconsistent in their recommended approval rates. Read More
Second Patient Dies in Zafgen Obesity Trial
Drugmaker UniQure Drops Glybera Gene Therapy Program in U.S.
Lilly’s Trulicity Succeeds in Phase 3 Study
Roche, Upsher-Smith Unit to Develop VAP-1 Inhibitor Read More
Real-world research offers the potential to better understand a medicine’s value in a clinical setting, but to fully harness its potential, drugmakers will need to restructure the way they think. Read More
The Italian Medicines Agency has issued a noncompliance statement to Rome-based radiopharmaceutical maker Iason Italia, hitting the company over deficiencies primarily related to sterility assurance. Read More
A month after the FDA announced a nationwide sweep that resulted in criminal and civil cases against 89 makers of dietary supplements, a former owner and operator of a Montana dietary supplement maker has been sentenced to prison for selling supplements in violation of two court orders. Read More